Key result
Isosorbide-mononitrate use in patients with type 2 diabetes mellitus was associated with significantly lower proteinuria (0.98 vs 1.61 g/day, P=0.001) compared to non-use.
Why the study?
Diabetic nephropathy occurs in roughly 40% of diabetic patients and is a leading cause of ESRD, creating a need for new treatment strategies.
Does isosorbide-mononitrate reduce proteinuria in patients with type 2 diabetes mellitus and diabetic nephropathy?
Observational
Does isosorbide-mononitrate reduce proteinuria in patients with type 2 diabetes mellitus and diabetic nephropathy?
Absolute Event Rate: 0.98% vs 1.61%
p-value: p=0.001
Isosorbide-mononitrate use is associated with significantly lower proteinuria in patients with type 2 diabetes mellitus, suggesting a potential adjunctive therapy for diabetic nephropathy.
Should not yet change T2DM proteinuria management; leaves open benefit pending randomized confirmation.
Background/Aim: Diabetic nephropathy (DN) occurs in approximately 40% of patients with Type 1 and Type 2 diabetes mellitus (DM) and is one of the most common causes of end-stage renal disease (ESRD). New treatment strategies are needed to prevent DN. This study aims to investigate the effect of the use of isosorbide-mononitrate (IMN) on diabetic nephropathy.Methods: In this study, patients with type 2 diabetes mellitus were divided into two groups, as those using and not using IMN to evaluate whether IMN reduces proteinuria. Biochemical parameters and proteinuria values were recorded and comparatively analyzed.Results: The urea and creatinine values of patients with type 2 DM who were using IMN were significantly higher and e-GFR values were significantly lower than those of the control group (P=0.049, P=0.001, P=0.013, respectively). However, the proteinuria amounts of Type 2 DM patients using IMN (0.98 g/day [0.52-1.43]) were significantly lower than those who were not (1.61 g/day [1.02-2.69] (P=0.001)).Conclusion: The addition of nitrate to angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in the treatment of patients with DN may be a new alternative for reducing proteinuria.
No takes yet. Share an insight, caveat, or question.
Demirci et al. (2021) conducted an observational in Type 2 diabetes mellitus with diabetic nephropathy. Isosorbide-mononitrate (IMN) vs. Not using IMN was evaluated on Proteinuria amount (g/day) (p=0.001). Isosorbide-mononitrate use in patients with type 2 diabetes mellitus was associated with significantly lower proteinuria (0.98 vs 1.61 g/day, P=0.001) compared to non-use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: